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ATP5C1, ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 2 
ATP5O, ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit 3 
ATP5B, ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 4 
ATP5A1, ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1 5 
ATP5F1, ATP synthase, H+ transporting, mitochondrial Fo complex, subunit B1 6 
COX, cytochrome c oxidase 7 
CS, citrate synthase 8 
eIF2, eukaryotic translation initiation factor 2 9 
eIF4, eukaryotic translation initiation factor 4 10 
ENO2, enolase 2 11 
FpSDH, flavoprotein subunit of succinate dehydrogenase   12 
FTI, farnesyltransferase inhibitor 13 
HGPS, Hutchinson-Gilford progeria syndrome 14 
MAF, mouse adult fibroblast 15 
mTOR, mammalian target of rapamycin  16 
OXPHOS, oxidative phosphorylation 17 
PKM, pyruvate kinase, muscle 18 
p70S6K, ribosomal protein S6 kinase, 70kDa, polypeptide 1 19 
SILAC, stable isotope labeling with amino acids in cell culture 20 
Zmpste24, zinc metalloproteinase STE24 homolog  21 
 22 
23 







Hutchinson-Gilford progeria syndrome (HGPS) is a rare segmental premature aging disorder that 26 
recapitulates some biological and physical aspects of physiological aging. The disease is caused by a 27 
sporadic dominant mutation in the LMNA gene that leads to the expression of progerin, a mutant form 28 
of lamin A that lacks 50 amino acids and retains a toxic farnesyl modification in its carboxy-terminus. 29 
However, the mechanisms underlying cellular damage and senescence and accelerated aging in HGPS 30 
are incompletely understood. Here, we analyzed fibroblasts from healthy subjects and HGPS patients 31 
using SILAC (stable isotope labeling with amino acids in cell culture). We found in HGPS cells a 32 
marked downregulation of mitochondrial oxidative phosphorylation proteins accompanied by 33 
mitochondrial dysfunction, a process thought to provoke broad organ decline during normal aging. We 34 
also found mitochondrial dysfunction in fibroblasts from adult progeroid mice expressing progerin 35 
(LmnaG609G/G609G knock-in mice) or prelamin A (Zmpste24-null mice). Analysis of tissues from these 36 
mouse models revealed that the damaging effect of these proteins on mitochondrial function is time- 37 
and dose-dependent. Mitochondrial alterations were not observed in brain, a tissue with extremely low 38 
progerin expression that seems to be unaffected in HGPS. Remarkably, mitochondrial function was 39 
restored in progeroid mouse fibroblasts treated with the isoprenylation inhibitors FTI-277 or 40 
pravastatin plus zoledronate, which are being tested in HGPS clinical trials. Our results suggest that 41 
mitochondrial dysfunction contributes to premature organ decline and aging in HGPS. Beyond its 42 
effects on progeria, prelamin A and progerin may also contribute to mitochondrial dysfunction and 43 
organ damage during normal aging, since these proteins are expressed in cells and tissues from non-44 














Nuclear lamins are type V intermediate filaments located beneath the inner nuclear membrane that 54 
provide structural support to the cell and play key roles in chromatin organization and gene expression 55 
[1, 2]. Three lamin genes have been identified in mammals [3]. LMNA encodes the alternatively 56 
spliced products lamin A and C (A-type lamins), which are expressed in most differentiated somatic 57 
cells, while LMNB1 and LMNB2 encode B-type lamins, which are expressed in nearly all cells and are 58 
essential for cell viability. Except for lamin C, nuclear lamins have a C-terminal CAAX motif (C, 59 
cysteine; A, aromatic amino acid; X, any residue) that is essential for protein maturation [4]. Post-60 
translational modification of the CAAX motif comprises addition of a 15 carbon farnesyl lipid to the C 61 
residue followed by removal of the last three residues and finally methylation of the newly modified 62 
cysteine. Prelamin A undergoes a further maturation step consisting of removal of the last 15 amino 63 
acids by the zinc metalloproteinase ZMPSTE24/FACE-1, which produces mature lamin A [5]. 64 
Mutations in LMNA or defective processing of prelamin A cause a group of human diseases 65 
collectively called laminopathies, including the systemic disease known as Hutchinson-Gilford 66 
progeria syndrome (HGPS) [6-8]. The disease was first described in 1886 [9], but it was not until 2003 67 
that its genetic basis was uncovered [10, 11]. Approximately 90% of HGPS patients have a non-68 
inherited heterozygous synonymous mutation at codon 608 (c.1824C>T: GGC>GGT; p.G608G). This 69 
mutation activates the use of an internal 5’ splice site in exon 11, which causes the deletion of 150 70 
nucleotides and the synthesis of progerin (also named LA∆50), a mutant form of prelamin A that lacks 71 
the ZMPSTE24 cleavage site and therefore retains a toxic farnesyl modification [10, 11]. Progerin, 72 
which exerts a dominant effect over the function of wild-type lamin A, causes structural abnormalities 73 
in the nuclear lamina, delays cytokinesis, hampers the DNA repair machinery and ultimately leads to 74 
the accumulation of DNA damage, increased genome instability and cell senescence [6]. Progerin 75 
accumulation might also contribute to physiological aging, since expression of this mutant form of 76 
prelamin A have been detected in cells from healthy individuals, predominantly at advanced ages [12-77 
17]. Likewise, abnormal accumulation of prelamin A in arterial tissue might accelerate senescence of 78 





vascular cells [18]. Telomere shortening and down-regulation of ZMPSTE24 during normal aging 79 
might contribute to progerin and prelamin A accumulation, respectively [17, 18] 80 
Despite the importance of progerin and prelamin A in accelerated aging and their potential role 81 
in normal aging, our knowledge of the mechanisms through which these proteins cause cellular 82 
damage remains limited. To dissect the molecular mechanisms underlying HGPS, we performed a 83 
large-scale proteomic study based on stable isotope labeling with amino acids in cell culture (SILAC) 84 
and liquid chromatography in tandem with mass spectrometry (LC-MS/MS) to identify protein 85 
alterations in dermal fibroblasts from HGPS patients. Our proteomic analysis and functional studies in 86 
human HGPS cells and progeroid mouse models expressing progerin and prelamin A identify 87 
mitochondrial dysfunction as a hallmark of accelerated aging, a cellular alteration which is thought to 88 
contribute to physiological aging and age-associated pathologies [19-23]. We also show that 89 
mitochondrial defects in progeroid human and mouse cells are ameliorated by treatment with 90 




EXPERIMENTAL PROCEDURES 95 
 96 
Ethics Statement. All animal work has been conducted according to Directive 2010/63EU and 97 
Recommendation 2007/526/EC regarding the protection of animals used for experimental and other 98 
scientific purposes, enforced in Spanish law under Real Decreto 1201/2005.  99 
 100 
Sample preparation for SILAC analysis. Primary skin fibroblasts from control subjects (GM01651, 101 
passage number 13 at purchase, from a healthy 13-year-old female; and GM08398, passage number 4 102 
at purchase, from an 8-year-old male) and from HGPS patients carrying the typical c.1824C>T 103 
mutation (AG01972, passage number 12 at purchase, from a 14-year-old female; and AG06297, 104 





passage number 19 at purchase, from an 8-year-old male) were obtained from the NIGMS Human 105 
Genetic Cell Repository (Coriell Institute). Figure 1 schematizes the study design. HGPS fibroblasts 106 
were grown asynchronously in ‘light’ (12C6-Lys and 12C6-Arg) DMEM (Dundee Cell) supplemented 107 
with 10% FBS and 100 units/mL of penicillin/streptomycin for one round of duplication to achieve 108 
enough cell material. Control fibroblasts were grown asynchronously for at least six doublings (to 109 
ensure full incorporation of labeled amino acids) in ‘heavy’ (13C6-Lys and 13C6-Arg) DMEM medium 110 
containing dialyzed FBS (Dundee Cell). After differential labeling, female and male HGPS cell lysates 111 
were prepared in RIPA buffer containing protease inhibitor cocktail (Roche) and mixed in a 1:1 ratio 112 
with the female and male control cell lysates, respectively. Mixtures were separated on 10% SDS-113 
polyacrylamide gels, visualized by Coomassie blue staining, excised horizontally into 27 sections and 114 
further de-stained in 25mM ammonium bicarbonate/acetonitrile. De-stained bands were cut into 115 
smaller pieces, dehydrated with acetonitrile and dried, rehydrated with 12.5 ng/µl trypsin solution in 116 
25 mM ammonium bicarbonate and incubated overnight at 37ºC. Digested peptides were extracted 117 
with acetonitrile and 5% formic acid, dried by vacuum centrifugation and reconstituted in 15 µl 2% 118 
acetonitrile in 0.1% formic acid. For both the male HGPS-control and female HGPS-control 119 
comparisons, two independent sets of lysates were mixed and processed as indicated above to provide 120 
a technical replicate.  121 
 122 
MS and SILAC quantification. The peptide mixtures from the different in-gel digestion fractions 123 
were analyzed by nanoflow LC-MS/MS (Agilent Technologies). The peptides were loaded onto a 0.3 124 
x 10mm C18 precolumn (SGE) and then eluted with a linear gradient of 5-95% ACN in a 0.1% 125 
aqueous solution of formic acid. The gradient was delivered over 120 min by a nano LC ultra 1D plus 126 
system (Eksigent) at a flow-rate of 200 nL/min, through a 75 µm x 15 cm fused silica capillary C18 127 
HPLC PepMap column (LC Packings), to a stainless nano-bore emitter (Proxeon). The peptides were 128 
scanned and fragmented with an LTQ XL linear ion trap mass spectrometer (Thermo Finningan) 129 
operated in data-dependent ZoomScan and MS/MS switching mode using the three most intensive 130 
precursors detected in a survey scan from 400 to 1600 amu (three µscans). The ZoomScan mass 131 





window was set to 12 Da, enabling monitoring of the entire 12C/13C isotopic envelope of most doubly 132 
and triply-charged peptides. Singly-charged ions were excluded from MS/MS analysis. Normalized 133 
collision energy was set to 35% and dynamic exclusion was applied during 3 min periods to avoid 134 
repetitive fragmentation of ions. 135 
Generated raw files were converted to .mgf files (Bioworks 3.3.1) for submission to the 136 
MASCOT database. A database containing the NCBI nr Homo sapiens sequences (as of July 2009, 137 
37391 sequences) was searched using the MASCOT protein identification software (v2.3 Matrix 138 
Science). Search criteria included trypsin specificity with one missed cleavage allowed, and with 139 
methionine oxidation, 13C6-Arg and 13C6–Lys as variable modifications. Minimum precursor and 140 
fragment-ion mass accuracies of 1.2 and 0.3 Da were used. To consider a protein as an accurate 141 
identification, at least one unique peptide (bold-red peptides meaning highest scoring peptide 142 
matching to protein with highest total score) with a Mascot score higher than 39 (p<0.05) and a 143 
minimum total protein score of 46 (p<0.01) were required. Peptide scores were derived from MS/MS 144 
data and total protein scores represent the sum of individual ion scores obtained on different peptides 145 
from the same protein. The false positive rate was calculated by searching the same spectra against the 146 
NCBI nr Homo sapiens decoy database. Relative quantification ratios of identified proteins based on 147 
peak area were calculated using Quixot v.1.3.26 open-source software 148 
(http://150.244.205.155/mediawiki/index.php/QuiXot). Protein ratios obtained by Quixot were verified 149 
manually for all peptides. 150 
 151 
Mice. Zmpste24-/-, LmnaG609G/G609G and LmnaG609G/+ have been described previously [24, 25]. 152 
Homozygous Zmpste24-/- and LmnaG609G/G609G mice are infertile but seem healthy until about 3 weeks 153 
of age. Subsequently, they show a progressive reduction in body weight and size and appearance of 154 
aging symptoms leading to premature death (average life expectancy of 14-15 weeks compared to 155 
more than 2 years in wild-type controls). Heterozygous LmnaG609G/+ mice have normal weight and size 156 
until about 8 months of age and then start to show aging symptoms and die at an average age of 34 157 
weeks. Wild-type littermates with the LMNA gene intact were used as controls.  158 






Generation of immortalized mouse fibroblasts. MAFs were isolated from the ears of 12-week-old 160 
wild-type, Zmpste24-/- and LmnaG609G/G609G mice as described previously [24]. Clumped cells were 161 
disrupted by pipetting and further filtered through a 45 µm cell strainer to obtain single cell 162 
suspensions. After 4-5 cell passages, primary MAFs were immortalized by retroviral transduction of 163 
SV40 large T antigen as described [26] and further maintained in high-glucose DMEM supplemented 164 
with 10% FBS. 165 
 166 
Measurement of mitochondrial oxygen consumption, enzyme activities and ATP production. 167 
Pyruvate driven oxygen consumption rates (respiration) were measured in intact living cells (2x106 168 
cells) at 37°C using an Oxytherm Electrode Unit equipped with a Clark electrode (Hansatech 169 
Instruments) [27]. Dinitrophenol was used to measure non-coupled respiration and values were 170 
expressed as nmol O2 consumed per million cells per minute. COX activity was measured in cell 171 
lysates (30–50 µg protein) as described [28], and was normalized to the activity of CS, a Krebs cycle 172 
enzyme whose activity correlates with mitochondrial mass. ATP synthesis in digitonin-permeabilized 173 
cells (2x106) was measured using a kinetic luminescence assay as described [29].  174 
 175 
Galactose/glucose growth assay. Immortalized MAFs (1x104) were seeded in 96-well plates and 176 
cultured for 4 days in DMEM containing either glucose (4.5 mg/ml) or galactose (0.9 mg/ml). Growth 177 
capacity was analyzed on a daily basis using the CyQUANT NF Cell proliferation assay kit 178 
(Invitrogen).  179 
 180 
Cell treatments. MAFs were cultured for 7 days in growth medium with or without 5 µM FTI-277 181 
(Sigma-Aldrich), or for 3 days with or without 5 µM pravastatine (Vasten; Sanofi Aventis) plus 5 µM 182 
zoledronate (ZOMETA, Novartis). In all cases, medium was replaced daily. After treatments, cells 183 
were washed with PBS and mitochondrial COX activity and ATP synthesis assays were carried our as 184 
indicated above. 185 






Western blot. Mouse tissues were dissected, washed in PBS and immediately snap-frozen in liquid 187 
nitrogen. Tissues were ground with a mortar and further homogenized with a Polytron tissue grinder. 188 
Tissue and cell extracts were prepared in RIPA buffer supplemented with protease inhibitors (Roche). 189 
Protein concentration was determined by the Bradford assay using BSA as standard (Protein Assay 190 
Kit, Bio-Rad). Total protein extracts (50 µg) were mixed with Laemmli sample buffer (62.5 mMTris-191 
HCl, pH 6.8, 2.3% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.005% bromophenol blue), boiled for 192 
10 min and resolved on 10% SDS-polyacrylamide gels. Proteins were transferred to PVDF membranes 193 
using the iBlot® Dry Blotting system (Invitrogen). The membranes were incubated for 1 h at room 194 
temperature in blocking buffer (5% non-fat dried milk in TBS-0.2% Tween-20) followed by 195 
incubation with primary antibodies diluted in blocking buffer (overnight, 4ºC). Primary antibodies 196 
were purchased from Invitrogen (anti-FpSDH, ref. 459200; anti-COXI, ref. 459600), MitoSciences (β-197 
ATPase, ref. MS503), Sigma (Anti-actin, ref. A2066, anti-catalase, ref. CAT-505), Abcam (anti-198 
Cytochrome C, ref. ab13575), and Santa Cruz Biotech. (anti-Lamin A/C, ref. sc-6214). After washes 199 
with TBS-0.2% Tween-20, membranes were incubated with HRP-conjugated secondary antibodies 200 
(Santa Cruz) for 1 h at room temperature, and specific proteins were visualized by enhanced 201 
chemiluminescence (GE Healthcare). 202 
 203 
Statistical analyses. Results are presented as means±SD. The central hypothesis that is being tested in 204 
this work is that progerin and prelamin A expression cause protein alterations and mitochondrial 205 
dysfunction. Data were analyzed by unpaired two-tailed t-test (comparisons of two groups) or one-way 206 
ANOVA with Dunnett’s multiple comparison post-hoc test (experiments with more than two groups). 207 
Differences were considered statistically significant at p< 0.05. 208 
209 








Proteome alterations in HGPS fibroblasts 213 
To identify pathways altered in HGPS, we performed SILAC experiments to compare the proteomes 214 
of dermal fibroblasts from 1 female HGPS patient vs. 1 age-matched female healthy control and from 215 
1 male HGPS patient vs. 1 age-matched male healthy control (Fig. 1). Each female [HGPS vs. control] 216 
and male [HGPS vs. control] sample set was processed and analysed twice, thus providing a technical 217 
replicate of each comparison (see Experimental Procedures). Complete incorporation of 13C6-Arg and 218 
13C6-Lys into healthy fibroblasts after six doublings in isotopically heavy medium was verified by 219 
mass spectrometry (MS) of a protein digest (data not shown). Consistent with the observation that 220 
senescence is a characteristic of HGPS cells [6, 7], our HGPS fibroblasts grew very poorly and could 221 
be maintained in culture for a very limited time (data not shown). Therefore, we could not carry out 222 
reverse-incorporation of isotope labels.  223 
MS analysis identified 3,304 proteins with at least one unique peptide in all four SILAC 224 
experiments and a false discovery rate of 0.6%, estimated from the number of hits against the reverse 225 
sequence/total hits ratio, p<0.01. However, only 819 and 720 proteins in male and female HGPS 226 
versus control comparisons, respectively, passed the criteria established for protein quantification, 227 
which include identification in at least two replicates of a given comparison set (male [HGPS vs. 228 
control] or female [HGPS vs. control]) and identification of at least two unique peptides with a 229 
MASCOT score >39 for the peptides and >46 for the full protein (see Supplemental Tables S1 and S2 230 
showing proteins identified in the male and female comparisons, respectively). The global overlap 231 
between the four SILAC experiments was 48%. We then focused on proteins with at least a 1.5-fold 232 
difference between control and HGPS and with 20% as the maximum relative standard deviation 233 
between peptides within each protein. Most of the identified proteins had a SILAC ratio close to 1.  234 





Amongst the 536 proteins showing ≥1.5 fold change and p<0.01 in both replicates of each 235 
female HGPS-control and male HGPS-control pool, we focused our attention on the 106 proteins that 236 
were significantly de-regulated in both the male and the female comparisons (26 expressed at higher 237 
level in HGPS: Supplemental Table S3 and 80 expressed at lower level in HGPS: Supplemental Table 238 
S4), since they are more likely to be a bona fide signature of altered progerin expression associated to 239 
HGPS. Proteins expressed at higher level in both male and female HGPS cells included proteins 240 
involved in glycolysis (PGK1, ENO2, PKM, and LDH), and those expressed at lower level included 241 
proteins of the translational apparatus (ribosomal proteins, eIF2, eIF4) and the mitochondrial oxidative 242 
phosphorylation system (OXPHOS) (proteins of ATP synthase complex V: ATP5C1, ATP5O, 243 
ATP5B, ATP5A1 and ATP5F1) (Fig. 2A). 244 
 245 
Human HGPS fibroblasts exhibit mitochondrial dysfunction 246 
Our proteomic analysis suggested that HGPS fibroblasts have profound metabolic alterations 247 
suggesting a metabolic switch from oxidative to glycolytic metabolism associated to defective 248 
OXPHOS. Accordingly, western blot analysis revealed markedly lower than normal expression of 249 
three crucial components of the mitochondrial respiratory chain in HGPS compared with control 250 
fibroblasts, including cytochrome c, the complex IV component cytochrome c oxidase subunit I 251 
(COXI), and the complex V protein β-ATPase (Fig. 2B). In contrast, we found no significant changes 252 
in the expression of succinate dehydrogenase flavoprotein, one of the four components of respiratory 253 
chain complex II, or of ubiquitously-expressed actin and catalase (Fig. 2B). These results demonstrate 254 
that HGPS fibroblasts have alterations in specific components localized both in the mitochondrial 255 
inner membrane (COXI) and the inter-membrane space (cytochrome c). 256 
We next performed functional assays to directly assess mitochondrial function in HGPS and 257 
control fibroblasts. Analysis of pyruvate plus malate-driven mitochondrial ATP production revealed 258 
significantly lower ATP synthesis in progeroid fibroblasts (Fig. 2C). Moreover, consistent with the 259 
western blot analysis, the activity of COX relative to that of citrate synthase (CS, typically used to 260 
normalize COX activity) was significantly lower in HGPS cells, with a COX/CS ratio 3-fold lower 261 





than in control cells (Fig. 2D). These results demonstrate that OXPHOS is severely impaired in human 262 
HGPS fibroblasts. 263 
 264 
Fibroblasts from progeroid LmnaG609G/G609G mice exhibit mitochondrial dysfunction 265 
We next investigated whether the OXPHOS dysfunction observed in primary HGPS fibroblasts also 266 
occurs in the LmnaG609G/G609G knock-in mouse model of the disease. These mice bear the LMNA 267 
c.1827C>T (p.G609G) mutation, equivalent to human c.1824C>T (p.G608G), express progerin as a 268 
consequence of aberrant exon11-12 LMNA splicing, and phenocopy the main clinical manifestations 269 
of human HGPS, including premature death [25]. Immortalized mouse adult fibroblasts (MAFs) 270 
derived from LmnaG609G/G609G mice showed a significantly lower mitochondrial ATP synthesis than 271 
wild-type control fibroblasts (Fig. 3A). Moreover, COX activity was significantly lower in 272 
LmnaG609G/G609G fibroblasts, while CS activity was unaffected (Fig. 3B). We also analyzed the 273 
functional state of the respiratory chain by measuring pyruvate-driven oxygen consumption in intact 274 
living cells. This analysis demonstrated that coupled and uncoupled respiration rates are both lower in 275 
LmnaG609G/G609G MAFs than in wild-type controls (Fig. 3C). 276 
Changing the carbon source of the culture medium from glucose to galactose shuts down 277 
glycolysis, forcing cells to meet energy demand exclusively via OXPHOS. Cells with a defective 278 
OXPHOS system will therefore be unable to adapt their metabolism in galactose medium and will thus 279 
grow more slowly [30]. Culture in galactose-containing medium over four days revealed slow growth 280 
of progeroid LmnaG609G/G609G MAFs compared with wild-type controls (Fig. 3D), confirming defective 281 
mitochondrial function in progeroid LmnaG609G/G609G MAFs. 282 
 283 
Mitochondrial dysfunction in tissues of LmnaG609G/G609G mice 284 
We next analysed the consequences of progerin expression in tissues from wild-type and progeroid 285 
mice. High progerin expression has been reported in several tissues of homozygous LmnaG609G/G609G 286 
mice compared with LmnaG609G/+ heterozygotes, including heart [31]. We found significantly lower 287 





COX/CS ratios in the hearts of 10-week-old homozygous LmnaG609G/G609G and heterozygous 288 
LmnaG609G/+ mice compared with wild-type littermates, an effect more pronounced in the homozygous 289 
progeroid mice (Fig. 4A). The COX/CS ratio also decreased with age, being lower in the hearts of 32-290 
week-old LmnaG609G/+ mice compared with 10-week-old LmnaG609G/+ mice (Fig. 4A). In 17-19-week-291 
old LmnaG609G/G609G mice we also detected a low COX/CS ratio in skeletal muscle, another tissue 292 
expressing high levels of progerin (Fig. 4B, left) [31]. These studies thus indicate that the deleterious 293 
effects of progerin on mitochondrial function are time- and dose-dependent. 294 
Recent studies have shown extremely low levels of prelamin A, lamin A and progerin in mouse 295 
and human neural cells [32, 33], which might explain why HGPS mouse models and patients seem to 296 
be free of pathology in the central nervous system. Consistent with these findings, progerin expression 297 
in the brains of 17-19-week-old LmnaG609G/G609G mice was extremely low, and this tissue showed no 298 
mitochondrial dysfunction in comparison with wild-type controls, as indicated by similar COX/CS 299 
ratios (Fig. 4B, right).  300 
 301 
Expression of prelamin A in progeroid mice lacking Zmpste24 is associated with mitochondrial 302 
dysfunction 303 
Loss of ZMPSTE24/FACE-1, the zinc metalloproteinase responsible for the final maturation of lamin 304 
A, causes the accumulation of prelamin A and lethal neonatal progeria in humans [34, 35]. Likewise, 305 
mice defective for Zmpste24 (Zmpste24-/-) accumulate permanently farnesylated prelamin A and 306 
display an accelerated aging phenotype [5, 24]. We also found mitochondrial dysfunction in MAFs 307 
isolated from Zmpste24-/- mice, as revealed by significantly lower-than-wild-type ATP synthesis (Fig. 308 
3A), COX/CS ratio (Fig. 3B), and coupled and uncoupled oxygen consumption (Fig. 3C), as well as 309 
impaired growth in galactose-containing medium (Fig. 3D). Furthermore, analysis of complex IV 310 
activity in Zmpste24-/- tissues confirmed the results obtained in LmnaG609G/G609G mice, with COX/CS 311 
ratios diminished in skeletal muscle (Fig. 4B) and heart (Fig. 4C), but with no effect in brain (Fig. 4B). 312 
 313 
 314 





Isoprenylation inhibitors rescue ATP synthesis and COX activity in progeroid fibroblasts 315 
Expression of permanently farnesylated prelamin A or progerin leads to aberrant nuclear morphology, 316 
a hallmark of HGPS. Treatment with farnesyl transferase inhibitors (FTIs) has demonstrated 317 
therapeutic efficacy both in HGPS cells and in progeroid mice [36-39]. Recently, the results of a 318 
clinical trial have provided preliminary evidence that the FTI lonafarnib may improve vascular 319 
stiffness, bone structure and audiological status in HGPS patients [40]. We therefore investigated the 320 
effect of FTI-277 on mitochondrial function in wild-type, Zmpste24-/- and LmnaG609G/G609G MAFs. Our 321 
results demonstrate that FTI-277 significantly increases ATP synthesis and COX/CS ratio in 322 
Zmpste24-/- and LmnaG609G/G609G MAFs, without affecting these parameters in wild-type cells (Fig. 5). 323 
A combination of a statin (pravastatin) plus an aminobisphosphonate (zoledronate) also inhibits 324 
isoprenylation of progerin and extends longevity in Zmpste24-/- mice [38]. Accordingly, ongoing Phase 325 
II clinical trials are assessing the efficacy of this combined treatment 326 
(http://www.progeriaresearch.org/clinical_trial.html, http://www.clinicaltrial.gov). Similarly to the 327 
treatment with FTI-277, addition of pravastatin+zoledronate to the culture medium did not affect the 328 
mitochondrial performance of wild-type MAFs, but significantly improved ATP synthesis and 329 
COX/CS ratio in Zmpste24-/- and LmnaG609G/G609G progeroid MAFs (Fig. 5). 330 
 331 
332 







To unravel the molecular mechanisms involved in HGPS, we performed unbiased proteomic analysis 335 
and functional assays in cellular and mouse models expressing progerin, the lamin A mutant protein 336 
responsible for this premature aging syndrome. Our SILAC analysis using human dermal fibroblasts 337 
from HGPS patients and age-matched healthy controls allowed the identification and quantification of 338 
3,304 proteins, of which 536 were differentially regulated after applying very stringent criteria for 339 
selection (175 up-regulated and 361 down-regulated in HGPS). These results represent a significant 340 
advance in comparison with previous studies that reported only 7 [41] and 30 [42] altered proteins in 341 
HGPS fibroblasts. In agreement with these previous studies, we found alterations in α-actinin, 342 
vimentin, several annexin isoforms, tropomyosin α-4, protein disulfide-isomerase, elongation factor 1, 343 
ribosomal protein L6, SNX3, galectin1 and hsp90, among others. It is important to note that our 344 
SILAC results have to be interpreted as an overall protein dysregulation profile in HGPS fibroblasts, 345 
which is likely to result from a mixture of damaging and compensation effects. Future studies are 346 
therefore required to unravel the hierarchy of protein alterations in HGPS. Of note, although we only 347 
performed SILAC in fibroblasts from one male and one female patient and age- and gender-matched 348 
controls, we focused our functional analysis in proteins involved in OXPHOS which exhibited 349 
statistically significant differences in both gender comparisons, since they are more likely to be a bona 350 
fide signature of altered progerin expression associated to HGPS. Indeed, we corroborated by western 351 
blot and functional assays the reduction in OXPHOS proteins and mitochondrial dysfunction in both 352 
male and female human HGPS fibroblasts, thus demonstrating the consistency of our SILAC studies. 353 
It is increasingly evident that A-type lamins play important roles in gene regulation [1]. Our 354 
SILAC results showed that more than 65% of the differentially regulated proteins are down-regulated 355 
in HGPS fibroblasts expressing progerin. These included proteins of the mTOR pathway, which 356 
positively regulates the activity of factors involved in protein translation [43]. Consistent with this, the 357 
largest cluster of down-regulated proteins in HGPS fibroblasts are key components of the translational 358 
apparatus, including 28 ribosomal proteins, 6 translation initiation factors and 3 translation elongation 359 
factors. Moreover, we found a 2-fold down-regulation of the mTOR target CD44. These findings in 360 





human cells reinforce previous data from progeroid Zmpste24-/- mice, which showed impaired mTOR 361 
signaling [44]. Despite the fact that progeria leads to mTOR inhibition, it was recently reported that 362 
treatment of HGPS cells with the mTOR inhibitor rapamycin promotes proteasomal progerin 363 
degradation, prevents nuclear abnormalities and delays the onset of cellular senescence [45]. Further 364 
studies are thus warranted to explain this apparent paradox and to investigate the functional 365 
consequences of the observed alterations in key components of translational apparatus, including 366 
ribosomal proteins, translational initiation factors and translation elongation factors.  367 
We also found that HGPS fibroblasts exhibit lower level of proteins related to mitochondrial 368 
biology, including OXPHOS, mitochondrial dysfunction, and oxidative stress, and previous studies 369 
have shown higher levels of reactive oxygen species and oxidized protein in HGPS fibroblasts 370 
compared to age-matched controls [46]. Remarkably, mitochondrial dysfunction can lead to excessive 371 
oxidative stress, which in turn can aggravate mitochondrial dysfunction [19]. To our knowledge, the 372 
present study provides the first demonstration that HGPS is associated with reduced expression of key 373 
components of the mitochondrial OXPHOS pathway. Importantly, we find that these alterations are 374 
accompanied by diminished oxidative phosphorylation capacity, as revealed by a marked reduction in 375 
the activity of mitochondrial complex IV (COX/CS, >65%) and the rate of mitochondrial ATP 376 
synthesis (∼50%) compared with age-matched healthy controls. Extending the relevance of these 377 
findings, our examination of fibroblasts from progeroid LmnaG609G/G609G mice expressing progerin also 378 
revealed reduced mitochondrial ATP synthesis, COX/CS ratio and oxygen consumption (a measure of 379 
overall respiratory chain activity), and an impaired capacity to grow in galactose-containing medium. 380 
Likewise, we found mitochondrial alterations in fibroblasts from Zmpste24-/- mice that accumulate 381 
high levels of prelamin A, which also causes premature aging in humans and mice [24, 34, 35]. 382 
Accordingly, tissues from LmnaG609G/G609G and Zmpste24-/- mice show mitochondrial alterations, 383 
revealed by impaired COX/CS ratio and mitochondrial ATP synthesis. Our results indicate that the 384 
effects of progerin are dose- and time-dependent, since analysis of protein lysates from heart tissue 385 
revealed more pronounced mitochondrial dysfunction in 10-week-old homozygous LmnaG609G/G609G 386 
versus heterozygous LmnaG609G/+ mice, and in old (32-week-old) versus young (10-week-old) 387 





LmnaG609G/+ mice. In agreement with the present results, we recently demonstrated mitochondrial 388 
dysfunction in vascular smooth muscle cells from LmnaG609G/+ mice [47]. Taken together, these 389 
findings underscore mitochondrial dysfunction as a general feature of progeroid syndromes caused by 390 
abnormal expression of either progerin or prelamin A. Interestingly, up-regulated proteins in HGPS 391 
included glycolytic enzymes (PGK1, ENO2, PKM) and lactate dehydrogenase, which are likely to 392 
compensate the decrease in mitochondrial ATP production caused by progerin or prelamin A 393 
expression. Indeed, mitochondrial dysfunction has been associated with different human pathologies, 394 
including neurodegenerative diseases, cancer, diabetes and cardiovascular disease [48]. Remarkably, 395 
impaired mitochondrial activity has been reported in HIV-treated patients displaying lipodystrophy 396 
[49], one of the main alterations shared by progeroid mouse models and HGPS patients. It is 397 
noteworthy that adipose tissue dysfunction in Zmpste24-/- mice is associated with up-regulation of 398 
proteins involved in the tricarboxylic acid cycle and OXPHOS, enhanced lipolysis, fatty acid 399 
biogenesis and β-oxidation, and low fatty acid re-esterification [50]. Additional work is thus warranted 400 
to elucidate the molecular mechanisms underlying the tissue specificity of metabolic alterations and 401 
mitochondrial dysfunction in premature aging syndromes. It would be also of interest to examine in  402 
progeroid mice metabolic rates, respiratory quotient and oxygen consumption measurements at early 403 
ages before symptoms develop as well as in animals with overt disease. 404 
A large body of evidence suggests that defective mitochondrial function is a major factor 405 
driving normal aging [19-23] that may also underlie progeroid manifestations in Polg mutator mice 406 
[51]. Our results show that premature aging caused by progerin or prelamin A is associated with 407 
defective mitochondrial function. Of note, recent studies have shown that miRNA-9 negatively 408 
controls lamin A and progerin expression in neural cells [32, 33], which might explain why HGPS-like 409 
mice and HGPS patients do not exhibit recognizable central nervous system abnormalities. 410 
Remarkably, we find that progeroid Zmpste24-/- and LmnaG609G/G609G mice express very low levels of 411 
prelamin A and progerin, respectively, in the brain, and in both models brain mitochondrial function is 412 
normal. It is also noteworthy that telomere ablation, which occurs during normal aging and is thought 413 
to impair cell and organismal homeostasis [22, 52, 53], has been shown to induce progerin expression 414 





and cellular senescence in normal human fibroblasts [17], and is associated with mitochondrial 415 
dysfunction in mice lacking telomerase activity [54]. Moreover, fibroblasts from HGPS patients 416 
exhibit shorter telomeres than control cells [55, 56]. Therefore, telomere and mitochondrial 417 
dysfunction, which have been recently proposed to play a central role in normal aging [22, 54], may 418 
also contribute to premature aging caused by abnormal accumulation of prelamin A or progerin, a 419 
possibility that merits further investigation. It is also tempting to speculate that these proteins may 420 
worsen mitochondrial function and organ decline during normal aging, since they have been shown to 421 
accumulate in several cells and tissues in non-HGPS individuals, most prominently at advanced ages 422 
[12-18]. 423 
Tissue culture and animal studies have demonstrated that farnesylated progerin exerts a 424 
dominant negative effect and plays a major role in the etiopathogenesis of HGPS [6]. In line with this 425 
notion, inhibition of progerin isoprenylation improves the nuclear abnormalities and the aging-like 426 
phenotypes, both in progeroid cells and in mice [36-39]. Recently, the results from a clinical trial 427 
enrolling 25 children with HGPS who were treated with the FTI lonafarnib for at least 2 years revealed 428 
increased rate of weight gain and improved measures of vascular stiffness, bone structure or 429 
audiological status for some patients [40]. The efficacy of inhibiting progerin isoprenylation is being 430 
also evaluated in ongoing clinical trials using a combination of statins plus aminobisphosphonates 431 
(http://www.progeriaresearch.org/clinical_trial.html and http://www.clinicaltrial.gov). We find that 432 
these treatments restore mitochondrial function in progeroid LmnaG609G/G609G and Zmpste24-/- 433 
fibroblasts, as revealed by improved complex IV and V activities. Whether these drugs also ameliorate 434 
mitochondrial function in HGPS patients and in other mitochondrial diseases remains to be examined. 435 
Further studies are also needed to unravel the mechanisms through which farnesylated progerin and 436 
prelamin A provoke mitochondrial abnormalities, which may pave the way to improved treatments of 437 
HGPS. Given that these proteins accumulate during normal aging, these studies may also improve our 438 
knowledge of the mechanisms leading to mitochondrial dysfunction during normal aging. 439 
 440 
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FIGURE LEGENDS 611 
 612 
 613 
Figure 1. Study design and schematic overview of the results of analysis by SILAC. Human 614 
primary skin fibroblasts obtained from 2 healthy controls (8-year-old male and 13-year-old female) 615 
and 2 HGPS patients (8-year-old male and 14-year-old female) were respectively grown in “heavy” or 616 
“light” DMEM medium. After differential labeling, the female and the male HGPS cell lysates were 617 
mixed with the female and male control cell lysates, respectively, and digested to a single pool of 618 
peptides. The female HGPS-control and male HGPS-control pools were analyzed in duplicate by 619 
liquid chromatography in tandem with mass spectrometry (LC-MS/MS), which allowed the 620 
identification and quantification of 3,304 proteins. Among these, 536 proteins showing ≥1.5 fold 621 
change and p<0.01 in both replicates of each female HGPS-control and male HGPS-control pool 622 
comparison were classified as deregulated only in male HGPS vs. male control (Table S1), only in 623 
female HGPS vs. female control (Table S2), and down- or up -regulated in both male and female 624 
HGPS vs. control (Tables S3-S4 respectively).  625 
 626 
Figure 2. Mitochondrial function is impaired in HGPS skin fibroblasts. (A) The cartoon shows 627 
proteins deregulated in both male and female HGPS fibroblasts. Higher expression was found in 628 
proteins related to metabolic energy pathways (red: PGK1, ENO2, PKM; LDH), and lower expression 629 
in mitochondrial Complex V (green). Complexes, substrates and products of the mitochondrial 630 
respiratory chain are also shown. (B) Western blot analysis showing markedly reduced levels of the 631 
indicated mitochondrial proteins in HGPS fibroblasts (1:AG01972 and 2: AG06297) versus cells from 632 
healthy controls (1:GM01651 and 2:GM08398). Actin was used as a loading control. (C) 633 
Mitochondrial ATP synthesis measured in digitonin-permeabilized cells using a kinetic luminescence 634 
assay. (D) Spectrophotometric determination of the activities of complex IV (COX) and citrate 635 
synthase (CS), a Krebs cycle enzyme used to normalize COX activity (COX/CS). Enzyme activities 636 
are expressed relative to control (=1). Data are means±SD from two independent experiments carried 637 





out in triplicate. Data in C and D show the mean for the two cell lines of each genotype. Statistical 638 
significance was determined by unpaired two-tailed t-test. **, P < 0.01; ***, P < 0.001. 639 
 640 
Figure 3. Mitochondrial function is impaired in skin fibroblasts from progeroid LmnaG609G/G609G 641 
and Zmpste24-/- mice. Immortalized MAFs of the indicated phenotype were analyzed. Data are 642 
means±SD of experiments performed in triplicate (A-C) or quadruplicate (D). (A) ATP production. 643 
(B) COX and CS activity and COX/CS ratio. (C) Oxygen consumption. (D) Capacity of MAFs to 644 
grow in medium containing galactose (Gal) or glucose (Glu) as the carbon source. Data show the ratio 645 
of cell growth in Gal/Glu media measured in logarithmic relative fluorescence units (RFU). Results in 646 
A, B and D are shown relative to wild-type (=1). Statistical significance was determined by one-way 647 
ANOVA with Dunnett’s post-hoc test. *, P < 0.05; ***, P < 0.001.   648 
 649 
Figure 4. Progerin and prelamin A expression is associated with mitochondrial dysfunction in 650 
different tissues in a time- and dose-dependent manner. COX and CS activities were measured in 651 
tissues extracted from mice of the indicated genotypes (wild-type, LmnaG609G/+, Zmpste24-/-: n=5; 652 
LmnaG609G/G609G: n=4). Results are shown relative to wild-type (=1). (A) COX/CS ratio in hearts of 10- 653 
and 32-week-old mice. (B) COX/CS ratio and western blot of skeletal muscle and brain extracts 654 
prepared from 17-19-week-old mice. Antibodies against Lamin A/C were used to detect wild-type 655 
lamin A and lamin C (white arrowheads) and prelamin A and progerin (black arrowheads). GAPDH 656 
was used as loading control. (C) COX/CS ratio in hearts of 17-19-week-old-mice. Statistical 657 
significance was assessed by one-way ANOVA with Dunnett’s post-hoc test. WT versus mutant mice: 658 
**, P < 0.01 and ***, P < 0.001; LmnaG609G/G609G versus LmnaG609G/+: †, P < 0.001; 10-week-old versus 659 
32-week-old LmnaG609G/+: #, P < 0.001. 660 
 661 
Figure 5. Isoprenylation inhibitors improve mitochondrial function in progeroid cells. 662 
Immortalized MAFs of the indicated genotype were grown in the absence (mock) or presence of FTI-663 
277 (7 days) or a combination of pravastatin plus zoledronate (3 days). Mitochondrial function was 664 
assessed by ATP synthesis and COX/CS ratio. Data are means±SD of three independent experiments 665 





carried out in duplicate. All results are shown relative to wild-type mock (=1). Statistical significance 666 
was determined by one-way ANOVA with Dunnett’s post-hoc test. For simplicity, only comparisons 667 
with mock of the same genotype are indicated: *, P < 0.05; **, P < 0.01. Consistent with the results of 668 
Figure 3, ATP synthesis and COX/CS ratios were significantly lower in mock progeroid cells than in 669 
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